Tandem Diabetes Care Inc
NASDAQ:TNDM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.05
53.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Tandem Diabetes Care Inc
Tandem Diabetes Care Inc
Total Equity
Tandem Diabetes Care Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
Total Equity
$237.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Equity
$25.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
18%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Equity
$20.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Equity
$20.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Equity
$39.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Equity
$15.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
|
Tandem Diabetes Care Inc
Glance View
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The company went IPO on 2013-11-13. The firm is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The firm's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The firm has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.
See Also
What is Tandem Diabetes Care Inc's Total Equity?
Total Equity
237.7m
USD
Based on the financial report for Sep 30, 2024, Tandem Diabetes Care Inc's Total Equity amounts to 237.7m USD.
What is Tandem Diabetes Care Inc's Total Equity growth rate?
Total Equity CAGR 10Y
13%
Over the last year, the Total Equity growth was -24%. The average annual Total Equity growth rates for Tandem Diabetes Care Inc have been -15% over the past three years , 7% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
